The Study
Intrinsic Deregulation of Vascular Smooth Muscle and Myofibroblast Differentiation in Mesenchymal Stromal Cells from Patients with Systemic Sclerosis
This study looked at cells from people with a rare disease and compared them to cells from healthy people, all grown in a petri dish. It found that the sick cells acted differently when given certain chemicals — but that doesn't mean those cells caused the disease. It's like noticing your phone charges slower than your friend's — it doesn't prove your phone is broken, just that it behaves differently.
Analysis score
Maximum 58 for a case-control study.
Where the score came from
In people with systemic sclerosis, the body's repair cells (MSCs) act weird when they smell TGF-β1 — a signal that normally helps heal wounds. Instead of stopping after fixing the damage, they go into overdrive, making too much collagen and not enough tools to clean it up.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 545 / 100
Quality score
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
Key takeaways
Summary
Based on the study abstract and findings.
- 1This means even if the body tries to heal, these faulty repair cells cause permanent scarring in skin and lungs — explaining why SSc patients develop stiff, thickened tissues.
- 2SSc-MSCs made 2–3x more collagen, migrated toward TGF-β1 (healthy cells didn't), and showed 50–70% higher activation of key signaling proteins (SMAD3, AKT, ERK).
- 3They also failed to turn on MMP-2/9 enzymes needed to break down collagen.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
PLoS ONE
Year
2016
Authors
B. Hegner, Theres Schaub, R. Catar, A. Kusch, Philine Wagner, K. Essin, C. Lange, G. Riemekasten, D. Dragun
Related Content
Claims (5)
Mesenchymal stromal cells from people with systemic sclerosis respond more strongly to TGF-β1 than cells from healthy individuals, resulting in higher collagen production, greater movement toward TGF-β1, slower cell division, and increased levels of contractile proteins.
Cells from people with systemic sclerosis produce less of the enzymes that break down collagen when exposed to TGF-β1, so collagen builds up instead of being cleared, contributing to tissue scarring.
Both healthy and systemic sclerosis cells turn into fibroblasts in the same way when exposed to PDGF-BB, suggesting this growth factor doesn't cause the disease through MSC dysfunction.
Cells from people with systemic sclerosis do not properly develop into vascular smooth muscle cells when exposed to CTGF or b-FGF, which may prevent blood vessels from repairing themselves and lead to vessel narrowing.
Cells from people with systemic sclerosis keep responding strongly to TGF-β1 because they fail to turn off their TGF-β receptor, while healthy cells turn it off after stimulation, leading to prolonged collagen production and fibrosis.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.